In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Servier options rights to three of MacroGenics' DART compounds; deal ends

Executive Summary

Building on a relationship that began with a separate deal almost a year ago, Servier SA has once again optioned rights to early-stage projects from MacroGenics Inc. (therapies for autoimmune and infectious diseases and cancer). This time, the French pharmaco has its sights on three of MacroGenics’ preclinical anticancer DART (Dual-Affinity Re-Targeting) compounds.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register